Drug Profile
Lixivaptan - Centessa Pharmaceuticals
Alternative Names: CRTX 080; Lixar; VPA 985; WAY VPA 985Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Centessa Pharmaceuticals; Chiesi USA
- Class Azepines; Benzamides; Small molecules; Urologics
- Mechanism of Action Vasopressin V2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autosomal recessive polycystic kidney disease
- Discontinued Autosomal dominant polycystic kidney disease; Hyponatraemia
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Autosomal-recessive-polycystic-kidney-disease in USA (PO)
- 13 Jun 2022 Palladio Biosciences discontinues a phase III ALERT trial in Autosomal dominant polycystic kidney disease in USA (PO) (NCT04152837)
- 03 Jun 2022 Discontinued - Phase-III for Autosomal dominant polycystic kidney disease in USA, Spain, Slovakia, Italy, Hungary, Bulgaria, Canada (PO) in June 2022